ClinicalTrials.gg
Active, not recruitingNCT05607004EVANGELINEUpdated Jul 8, 2026

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

A Phase 2 interventional study of (Z)-endoxifen and goserelin in Breast Neoplasms, Invasive Breast Cancer and Estrogen-receptor-positive Breast Cancer, sponsored by Atossa Therapeutics, Inc.. Active, not recruiting at 14 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part.

The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules daily. Twelve participants will be randomly assigned (50/50 chance) to take (Z)-endoxifen alone or (Z)-endoxifen with a monthly injection of goserelin a drug that temporarily stops the ovaries from making estrogen. This part will help determine the best dose of (Z)-endoxifen by measuring the drug levels in the blood and how long the body takes to remove it.

The Treatment Cohort has been simplified to a single study arm (Z)-endoxifen + goserelin. Up to 20 participants will be enrolled that have a baseline Ki-67 ≤ 10% and 45 participants will be enrolled that have a baseline Ki-67>10%.

A key goal of the study is to see if (Z)-endoxifen can slow down or stop tumor growth as measured by a reduction in Ki-67 levels. Tumor tissue samples will be taken by breast biopsy after about 4 weeks of treatment to check levels of this biomarker. If the tumor shows signs of response, participants can continue treatment for up to 24 weeks or until they have surgery.

Study participation is up to 6 months (24 weeks of treatment) followed by surgery and a one-month follow up visit.

02

Conditions studied

  • Breast Neoplasms
  • Invasive Breast Cancer
  • Estrogen-receptor-positive Breast Cancer
  • HER2-negative Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • ER+/HER2-
  • endocrine therapy
  • neoadjuvant
  • (Z)-endoxifen
  • exemestane
  • goserelin
  • Ki-67
  • estrogen receptor negative
  • human epidermal growth factor receptor 2 negative
  • Stage II
  • tamoxifen
  • PKCB1
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 87 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female sex assigned at birth. Female to male transgender individuals who have not had any hormonal therapy may be considered for the trial after review and approval from the medical monitor and study sponsor.
  2. Age 18 years or older
  3. Not lactating, pregnant, or planning to become pregnant in the next year and agrees to take adequate steps to prevent becoming pregnant beginning at , during treatment and for 9 months after last dose and agree to not breast feed during treatment and for 3 months after last dose.
  4. Must agree to use at least one non-hormonal highly effective method of for the entire duration of study participation beginning at informed consent. Highly effective methods of birth control are defined as those, alone or in combination, that resulted in a low failure rate of \<1% per year when used consistently and correctly such as intrauterine devices (IUDs, non-hormonal such as copper IUD), bilateral tubal occlusion, sexual abstinence or vasectomized partner
  5. Premenopausal defined as any female who:

    1. is menstruating or
    2. is not menstruating (last menstrual period > 3 months prior to registration) but has a plasma estradiol in the premenopausal range as assessed locally
  6. Pathologic confirmation of strongly estrogen receptor positive (ER+) (defined as estrogen receptor [ER] ≥ 67% or Allred Score 6-8) by local institution protocol
  7. ECOG Performance Status (ECOG PS) of 0 to 2
  8. Nottingham (Elston-Ellis) Grade 1 or 2
  9. - breast cancer ( confirmed) using American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
  10. Clinical T2 or T3 invasive breast cancer (per American Joint Committee on Cancer [AJCC] 8th edition clinical staging)
  11. Clinical N0 or N1 invasive breast cancer (per American Joint Committee on Cancer [AJCC] 8th edition clinical staging)
  12. MRI ≤ 35 days of registration
  13. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects
  14. Willing to provide blood and breast tissue samples for research purposes at specified timepoints for the duration of their participation in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Bilateral invasive breast cancer; Inflammatory breast cancer defined as erythema of the breast and/or documented dermal lymphatic invasion or bilateral invasive breast cancer (patients with pre-malignant disease or DCIS/LCIS in contralateral breast are eligible)
  2. Prior diagnosis or treatment for breast cancer, including carcinoma in situ, or history of any other active within the past 2 years prior to study entry with the exception of:

    1. Adequately treated in situ carcinoma of the cervix uteri
    2. Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
    3. Any other malignancy with a of less than 2 years
  3. Any uncontrolled intercurrent illness including, but not limited to:

    1. Ongoing or active infection requiring systemic treatment with strong inhibitors/inducers of CYP450 enzymes (including bacterial infection, fungal infection, or detectable viral infection).
    2. Symptomatic congestive heart failure,
    3. Unstable angina pectoris,
    4. Uncontrolled symptomatic cardiac arrhythmias
    5. Uncontrolled hypertension
    6. Uncontrolled diabetes ( [HbA1c] >7%)
    7. Marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval > 470 milliseconds [msec]) using Fridericia's QT correction formula seen ≤ 28 days of registration
  4. Any of the following co-morbid conditions:

    1. Known cataracts or retinopathy
    2. History of deep vein thrombosis (DVT)/pulmonary embolism (PE)
    3. Known activated protein C (APC) resistance, an inherited coagulation disorder
    4. End stage kidney disease requiring dialysis
  5. Evidence of the following laboratory abnormalities ≤ 28 days prior to registration:

    1. Total ≥ 1.5 x (ULN)
    2. (AST) or alanine amino transferase (ALT) ≥ 2.5 x ULN
    3. count (PLT) ≤ 75,000/mm3
    4. (Hb) ≤ 10 g/dL
  6. Hormonal therapies including and hormone replacement therapy, or prior use of androgen-based therapy during the study or within 1 week of registration. If subject has a prior medical history of Depo-Provera®, it is recommended that the last dose of 3-month contraceptive agents are > 2.5 months from registration.
  7. Allergy to endoxifen, goserelin, or exemestane or any of their components
  8. Participation in another clinical trial ≤ 6 months of registration
  9. Known disease
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    PK Cohort

    (Z)-endoxifen capsules orally once daily for 4 weeks. Initial (Z)-endoxifen dose evaluated will be 40 mg with an option to evaluate 20 mg or 80 mg. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery.

    Drug: (Z)-endoxifen

  • Experimental
    Treatment Cohort - Single Treatment Arm

    (Z)-endoxifen 40mg capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen 40mg dose based on results of PK Cohort. If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. And then go on to surgery within 3 weeks of Cycle 6 day 26. If Ki-67 \> 10% at Week 4, participant will complete early termination assessments.

    Drug: (Z)-endoxifen · Drug: goserelin

  • Experimental
    PK Cohort 80 mg

    (Z)-endoxifen 80 mg capsules orally once daily for 4 weeks. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery.

    Drug: (Z)-endoxifen

  • Experimental
    PK Cohort 80 mg + OFS

    (Z)-endoxifen 80 mg capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 \> 10% at Week 4, participant will be withdrawn and go on to surgery.

    Drug: (Z)-endoxifen · Drug: goserelin

Interventions

  • (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

    Also known as: endoxifen

  • goserelin 3.6 mg subcutaneous implant

    Also known as: Zoladex

06

What researchers measure

Primary outcomes

  1. PK Cohort - (Z)-endoxifen steady-state plasma concentrations

    (Z)-endoxifen steady-state plasma concentrations (Css) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: After 4 weeks of treatment

  2. For Analysis of Cohort A (Treatment Cohort): determine whether the week 4 Ki-67≤10% rate is at least 65%

    For analysis Cohort A (subjects that have a baseline Ki-67\>10%): the primary objective is to determine whether the Week 4 Ki-67 ≤ 10% rate is at least 65% among premenopausal women with primary estrogen receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

    Time frame: After 4 weeks of treatment

  3. For analysis Cohort B (Treatment Cohort): determine the objective tumor response rate at 24 weeks

    For analysis Cohort B (subjects have baseline Ki-67≤ 10%): the primary objective is to determine the objective tumor response rate at 24 weeks among premenopausal women with ER+, HER2-, Ki-67 ≤ 10% breast cancer receiving (Z) endoxifen plus goserelin.

    Time frame: After 24 weeks of treatment

Secondary outcomes

  1. PK Cohort - Area under the plasma (Z)-endoxifen concentration-time curve from time zero to last measurable concentration

    Area under the plasma (Z)-endoxifen concentration-time curve from time zero to last measurable concentration (AUC0-24) on Days 1 and 28 of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: Days 1 and 28

  2. PK Cohort - Area under the plasma (E)-endoxifen concentration-time curve from time zero to last measurable concentration

    Area under the plasma (E)-endoxifen concentration-time curve from time zero to last measurable concentration (AUC0-24) on Days 1 and 28 of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: Days 1 and 28

  3. PK Cohort - Accumulation and accumulation half-life

    Accumulation and accumulation half-life (Day 28 AUC0-24/Day 1 AUC0-24) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: Days 1 and 28

  4. PK Cohort - (Z)-endoxifen steady-state clearance

    (Z)-endoxifen CLss (steady-state clearance) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  5. PK Cohort - (E)-endoxifen steady-state clearance

    (E)-endoxifen CLss (steady-state clearance) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  6. PK Cohort - Maximum plasma (Z)-endoxifen concentration

    Maximum plasma (Z)-endoxifen concentration (Cmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  7. PK Cohort - Maximum plasma (E)-endoxifen concentration

    Maximum plasma (E)-endoxifen concentration (Cmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  8. PK Cohort - Time to plasma (Z)-endoxifen maximum concentration

    Time to plasma (Z)-endoxifen maximum concentration (Tmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  9. PK Cohort - Time to plasma (E)-endoxifen maximum concentration

    Time to plasma (E)-endoxifen maximum concentration (Tmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)

    Time frame: up to 28 days

  10. PK Cohort - plasma (Z)-endoxifen concentration

    Trough concentrations of (Z)-endoxifen for subjects in the Treatment Extension

    Time frame: Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.

  11. PK Cohort - plasma (E)-endoxifen concentration

    Trough concentrations of (Z)-endoxifen for subjects in the Treatment Extension

    Time frame: Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.

  12. PK Cohort- Endocrine sensitive disease rate based on Ki-67 percent after 4 weeks of treatment

    Endocrine sensitive disease rate will be estimated as the percentage of subjects whose 4-week tumor biopsy finds Ki-67 less than or equal to 10 percent among evaluable subjects who began protocol treatment

    Time frame: After 4 weeks of treatment

  13. All Cohorts - Incidence and severity of adverse events per CTCAE by treatment

    Incidence and severity of adverse events per CTCAE

    Time frame: Informed consent up to follow up visit or up to 30 weeks

  14. All Cohorts - Incidence of Serious Adverse Events assessed by CTCAE version 5.0

    Serious adverse events and adverse events leading to discontinuation of neoadjuvant treatment

    Time frame: Informed consent up to follow up visit or up to 30 weeks

  15. All Cohorts - Incidence of Dose Reductions

    The incidence of dose reductions

    Time frame: Informed consent up to end of treatment or up to 24 weeks

  16. All Cohorts - Change in estradiol and estrone

    Percent change from baseline in E1 and E2 at 4 weeks, and 24 weeks

    Time frame: Day 1, up to 4 weeks and up to end of treatment or up to 24 weeks.

  17. All Cohorts - Percentage of subjects whose serum thymidine kinase 1 (TK1) is not detectable at 4 weeks and 24 weeks.

    Percent of subjects whose serum TK1 is not detectable at 4 weeks and 24 weeks

    Time frame: Day 1, up to 4 weeks and up to end of treatment or up to 24 weeks.

  18. Treatment Cohorts - Assess additional PK parameters of (Z)-endoxifen and (E)-endoxifen

    Tissue and plasma (Z)-endoxifen and (E)-endoxifen concentrations at 4 weeks and 24 weeks

    Time frame: Day 1, up to 4 weeks, up to 12 weeks and up to 24 weeks

  19. Treatment Cohorts - Radiographic Response Rate in the breast

    Radiographic response rate in the breast at 4, 12, and 24 weeks as assessed by RECIST 1.1 criteria

    Time frame: Baseline Assessment, up to 4 weeks, up to 12 weeks, and up to 24 weeks

  20. Treatment Cohorts - Pathologic Complete Response per American Joint Committee on Cancer staging system at time of surgery

    Pathologic Complete Response (pCR) at surgery defined as the absence of residual invasive breast cancer on hematoxylin and eosin evaluation of the resected breast specimen and of all sampled lymph nodes (sentinel ± axillary) removed following completion of neoadjuvant systemic therapy

    Time frame: At time of surgery or up to 27 weeks

  21. Treatment Cohorts - Pre-Operative Endocrine Prognostic Index at time of surgery

    Rate of Pre-Operative Endocrine Prognostic Index (PEPI) 0 at time of surgery using residual tumor specimen

    Time frame: At time of surgery or up to 27 weeks

  22. Treatment Cohorts - Residual Cancer Burden at time of surgery

    Rate of residual cancer burden class of 0-I at time of surgery

    Time frame: At time of surgery or up to 27 weeks

  23. Treatment Cohorts - Conversion Rate

    Evaluate the conversion rate from breast conservation surgery ineligible to breast conservation surgery eligible. Evaluation is based on surgeon's impression of the type of surgery participant is eligible for (candidate for lumpectomy, candidate for modified radical mastectomy, inoperable) at baseline compared to surgeon's impression after completion of neoadjuvant treatment

    Time frame: From baseline to time of surgery or up to 27 weeks

  24. Treatment Cohorts - Actual Conversion Rate

    Evaluate the actual rate of breast conservation surgery. Evaluation will be based on the extent of the surgical procedure at the time of surgery (lumpectomy, partial or segmental mastectomy, simple/total mastectomy, skin and/or nipple sparing mastectomy, radical mastectomy or other)

    Time frame: At time of surgery or up to 27 weeks

  25. Treatment Cohorts - Change in menopause quality of life (MENQOL)

    Evaluate changes in menopause symptoms after neoadjuvant treatment

    Time frame: baseline, up to 4 weeks, and up to 24 weeks

  26. Treatment Cohorts - Nodal response rate

    Rate of nodal pCR in subjects with biopsy proven nodal disease

    Time frame: At time of surgery or up to 27 weeks

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 7, 2022
StartActual
Feb 14, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Apr 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05607004
Lead sponsor
Atossa Therapeutics, Inc.
Collaborators
InClin, Inc.
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Feb 14, 2023
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Matthew P Goetz, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endoxifen

Start the discussion